Basic Information
RNALocate ID: | RLID:01001666 |
RNA Symbol: | hsa-miR-221-3p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-221 |
RNA ID: | miRBase:MIMAT0000278 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001665 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001667 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001668 | Mitochondrion | HEK-293 cells|HeLa cells|Myotube | 27396686 |
RLID:01001669 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001670 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001671 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001672 | Nucleolus | Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001673 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11001529 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001530 | Exosome | Colorectal cancer cell lines (HCT-15|SW480|WiDr) | 22895844 |
RLID:11001531 | Exosome | Brain tissue | 23382797 |
RLID:11001532 | Exosome | Plasma | 23663360 |
RLID:11001533 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001534 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001535 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001536 | Microvesicle | Plasma | 23077538 |
RLID:11001537 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000063 | Exosome | Blood|B lymphoblastoid cells|Breast tissue|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Mast cells|Tongue tissue | |
RLID-D:11000337 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-221-3p | Splenic marginal zone lymphoma | MNDR-E-MI-30532 |
MNDR | hsa-miR-221-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-30533 |
MNDR | hsa-miR-221-3p | Oral squamous cell carcinoma | MNDR-E-MI-30534 |
MNDR | hsa-miR-221-3p | Follicular cleaved lymphoma | MNDR-E-MI-30535 |
MNDR | hsa-miR-221-3p | Medulloblastoma | MNDR-E-MI-30536 |
MNDR | hsa-miR-221-3p | Small intestinal neuroendocrine tumor | MNDR-E-MI-30537 |
MNDR | hsa-miR-221-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-30538 |
MNDR | hsa-miR-221-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-30539 |
MNDR | hsa-miR-221-3p | Lymphoma | MNDR-E-MI-30540 |
MNDR | hsa-miR-221-3p | Lymphoma non-hodgkin | MNDR-E-MI-30541 |
MNDR | hsa-miR-221-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-30542 |
MNDR | hsa-miR-221-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-30543 |
MNDR | hsa-miR-221-3p | Her2-receptor positive breast cancer | MNDR-E-MI-30544 |
MNDR | hsa-miR-221-3p | Acute promyelocytic leukemia | MNDR-E-MI-30545 |
MNDR | hsa-miR-221-3p | Breast cancer luminal b | MNDR-E-MI-30546 |
MNDR | hsa-miR-221-3p | Niemann-pick disease type c | MNDR-E-MI-30547 |
MNDR | hsa-miR-221-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-30548 |
MNDR | hsa-miR-221-3p | Colorectal carcinoma | MNDR-E-MI-30549 |
MNDR | hsa-miR-221-3p | Small intestine cancer | MNDR-E-MI-30550 |
MNDR | hsa-miR-221-3p | Dermatomyositis | MNDR-E-MI-30551 |
MNDR | hsa-miR-221-3p | Prostate cancer | MNDR-E-MI-30552 |
MNDR | hsa-miR-221-3p | Prostate carcinoma | MNDR-E-MI-30553 |
MNDR | hsa-miR-221-3p | Chronic lymphocytic leukemia | MNDR-E-MI-30554 |
MNDR | hsa-miR-221-3p | Gastric cancer | MNDR-E-MI-30555 |
MNDR | hsa-miR-221-3p | Gastric lymphoma | MNDR-E-MI-30556 |
MNDR | hsa-miR-221-3p | Alzheimer disease | MNDR-E-MI-30557 |
MNDR | hsa-miR-221-3p | Bladder cancer | MNDR-E-MI-30558 |
MNDR | hsa-miR-221-3p | Dysautonomia familial | MNDR-E-MI-30559 |
MNDR | hsa-miR-221-3p | Polycystic ovary syndrome | MNDR-E-MI-30560 |
MNDR | hsa-miR-221-3p | Myotonic dystrophy | MNDR-E-MI-30561 |
MNDR | hsa-miR-221-3p | Muscular dystrophy duchenne | MNDR-E-MI-30562 |
MNDR | hsa-miR-221-3p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-30563 |
MNDR | hsa-miR-221-3p | Head and neck cancer | MNDR-E-MI-30564 |
MNDR | hsa-miR-221-3p | Leukemia | MNDR-E-MI-30565 |
MNDR | hsa-miR-221-3p | Huntington disease | MNDR-E-MI-30566 |
MNDR | hsa-miR-221-3p | Chorea | MNDR-E-MI-30567 |
MNDR | hsa-miR-221-3p | Cardiovascular disease | MNDR-E-MI-30568 |
MNDR | hsa-miR-221-3p | Carotid stenosis | MNDR-E-MI-30569 |
MNDR | hsa-miR-221-3p | Brain cancer | MNDR-E-MI-30570 |
MNDR | hsa-miR-221-3p | Lung cancer | MNDR-E-MI-30571 |
MNDR | hsa-miR-221-3p | Down syndrome | MNDR-E-MI-30572 |
MNDR | hsa-miR-221-3p | Parkinson disease | MNDR-E-MI-30573 |
MNDR | hsa-miR-221-3p | Niemann-pick disease | MNDR-E-MI-30574 |
MNDR | hsa-miR-221-3p | Major depressive disorder | MNDR-E-MI-30575 |
MNDR | hsa-miR-221-3p | Basal-like breast cancer | MNDR-E-MI-30576 |
MNDR | hsa-miR-221-3p | Vascular diseases | MNDR-E-MI-30577 |
MNDR | hsa-miR-221-3p | Thyroid cancer | MNDR-E-MI-30578 |
MNDR | hsa-miR-221-3p | Pituitary neoplasms | MNDR-E-MI-30579 |
MNDR | hsa-miR-221-3p | Pancreatic cancer | MNDR-E-MI-30580 |
MNDR | hsa-miR-221-3p | Hepatitis C | MNDR-E-MI-30581 |
MNDR | hsa-miR-221-3p | Melanoma | MNDR-E-MI-30582 |
MNDR | hsa-miR-221-3p | Atherosclerosis | MNDR-E-MI-30583 |
MNDR | hsa-miR-221-3p | Nephroblastoma | MNDR-E-MI-30584 |
MNDR | hsa-miR-221-3p | Colon cancer | MNDR-E-MI-30585 |
MNDR | hsa-miR-221-3p | Essential thrombocythemia | MNDR-E-MI-30586 |
MNDR | hsa-miR-221-3p | Ischemic attack transient | MNDR-E-MI-30587 |
MNDR | hsa-miR-221-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-30588 |
MNDR | hsa-miR-221-3p | Ovarian cancer | MNDR-E-MI-30589 |
MNDR | hsa-miR-221-3p | Prostate adenocarcinoma | MNDR-E-MI-30590 |
MNDR | hsa-miR-221-3p | Carcinoma ductal breast | MNDR-E-MI-30591 |
MNDR | hsa-miR-221-3p | Glioblastoma | MNDR-E-MI-30592 |
MNDR | hsa-miR-221-3p | Astrocytoma | MNDR-E-MI-30593 |
MNDR | hsa-miR-221-3p | Glioma | MNDR-E-MI-30594 |
MNDR | hsa-miR-221-3p | Chordoma | MNDR-E-MI-30595 |
MNDR | hsa-miR-221-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-30596 |
MNDR | hsa-miR-221-3p | Epilepsy temporal lobe | MNDR-E-MI-30597 |
MNDR | hsa-miR-221-3p | Osteosarcoma | MNDR-E-MI-30598 |
MNDR | hsa-miR-221-3p | Pediatric osteosarcoma | MNDR-E-MI-30599 |
MNDR | hsa-miR-221-3p | Coronary artery disease | MNDR-E-MI-30600 |
MNDR | hsa-miR-221-3p | Carotid artery thrombosis | MNDR-E-MI-30601 |
MNDR | hsa-miR-221-3p | Inclusion body myositis | MNDR-E-MI-30602 |
MNDR | hsa-miR-221-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-30603 |
MNDR | hsa-miR-221-3p | Liver cancer | MNDR-E-MI-30604 |
MNDR | hsa-miR-221-3p | Uterine cancer | MNDR-E-MI-30605 |
MNDR | hsa-miR-221-3p | Cervical adenocarcinoma | MNDR-E-MI-30606 |
MNDR | hsa-miR-221-3p | Gastric adenocarcinoma | MNDR-E-MI-30607 |
MNDR | hsa-miR-221-3p | Pituitary adenoma | MNDR-E-MI-30608 |
MNDR | hsa-miR-221-3p | Lung squamous cell carcinoma | MNDR-E-MI-30609 |
MNDR | hsa-miR-221-3p | Carcinoma lung non-small-cell | MNDR-E-MI-30610 |
MNDR | hsa-miR-221-3p | Lung adenocarcinoma | MNDR-E-MI-30611 |
MNDR | hsa-miR-221-3p | Adrenocortical carcinoma | MNDR-E-MI-30612 |
MNDR | hsa-miR-221-3p | Thyroid carcinoma | MNDR-E-MI-30613 |
MNDR | hsa-miR-221-3p | Papillary thyroid carcinoma | MNDR-E-MI-30614 |
MNDR | hsa-miR-221-3p | Ovarian carcinoma | MNDR-E-MI-30615 |
MNDR | hsa-miR-221-3p | Bladder urothelial carcinoma | MNDR-E-MI-30616 |
MNDR | hsa-miR-221-3p | Pancreatic adenocarcinoma | MNDR-E-MI-30617 |
MNDR | hsa-miR-221-3p | Cervical cancer | MNDR-E-MI-30618 |
MNDR | hsa-miR-221-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-30619 |
MNDR | hsa-miR-221-3p | Carcinoma renal cell | MNDR-E-MI-30620 |
MNDR | hsa-miR-221-3p | Chromophobe renal cell carcinoma | MNDR-E-MI-30621 |
MNDR | hsa-miR-221-3p | Biliary tract cancer | MNDR-E-MI-30622 |
MNDR | hsa-miR-221-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-30623 |
MNDR | hsa-miR-221-3p | Cholangiocarcinoma | MNDR-E-MI-30624 |
MNDR | hsa-miR-221-3p | Esophageal cancer | MNDR-E-MI-30625 |
MNDR | hsa-miR-221-3p | Oncocytoma | MNDR-E-MI-30626 |
MNDR | hsa-miR-221-3p | Lung small cell carcinoma | MNDR-E-MI-30627 |
MNDR | hsa-miR-221-3p | Gastric carcinoma | MNDR-E-MI-30628 |
MNDR | hsa-miR-221-3p | Fibromyalgia | MNDR-E-MI-30629 |
MNDR | hsa-miR-221-3p | Adenoma | MNDR-E-MI-30630 |
MNDR | hsa-miR-221-3p | Breast invasive carcinoma | MNDR-E-MI-30631 |
MNDR | hsa-miR-221-3p | Hepatocellular carcinoma | MNDR-E-MI-30632 |
MNDR | hsa-miR-221-3p | Embryonal cancer | MNDR-E-MI-30633 |
MNDR | hsa-miR-221-3p | B-cell lymphoma | MNDR-E-MI-30634 |
MNDR | hsa-miR-221-3p | Rheumatoid arthritis | MNDR-E-MI-30635 |
MNDR | hsa-miR-221-3p | T-cell leukemia | MNDR-E-MI-30636 |
MNDR | hsa-miR-221-3p | Retinoblastoma | MNDR-E-MI-30637 |
MNDR | hsa-miR-221-3p | Neuroblastoma | MNDR-E-MI-30638 |
MNDR | hsa-miR-221-3p | Thyroid hurthle cell carcinoma | MNDR-E-MI-30639 |
MNDR | hsa-miR-221-3p | Hodgkin lymphoma | MNDR-E-MI-30640 |
MNDR | hsa-miR-221-3p | Burkitt lymphoma | MNDR-E-MI-30641 |
MNDR | hsa-miR-221-3p | Cutaneous melanoma | MNDR-E-MI-30642 |
MNDR | hsa-miR-221-3p | Acute myelocytic leukemia | MNDR-E-MI-30643 |
MNDR | hsa-miR-221-3p | Colorectal cancer | MNDR-E-MI-30644 |
MNDR | hsa-miR-221-3p | Nasopharynx carcinoma | MNDR-E-MI-30645 |
MNDR | hsa-miR-221-3p | Type 2 diabetes mellitus | MNDR-E-MI-30646 |
MNDR | hsa-miR-221-3p | Acute myocardial infarction | MNDR-E-MI-30647 |
MNDR | hsa-miR-221-3p | Multiple myeloma | MNDR-E-MI-30648 |
MNDR | hsa-miR-221-3p | Acute lymphoblastic leukemia | MNDR-E-MI-30649 |
MNDR | hsa-miR-221-3p | Ependymoma | MNDR-E-MI-30650 |
MNDR | hsa-miR-221-3p | Cardiomegaly | MNDR-E-MI-30651 |
MNDR | hsa-miR-221-3p | Nasopharyngeal cancer | MNDR-E-MI-30652 |
MNDR | hsa-miR-221-3p | Prostatic neoplasms | MNDR-E-MI-30653 |
MNDR | hsa-miR-221-3p | Polymyositis | MNDR-E-MI-30654 |
MNDR | hsa-miR-221-3p | Epstein-barr virus infections | MNDR-E-MI-30655 |
MNDR | hsa-miR-221-3p | Mptp poisoning | MNDR-E-MI-30656 |
MNDR | hsa-miR-221-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-30657 |
MNDR | hsa-miR-221-3p | Stroke lacunar | MNDR-E-MI-30658 |
MNDR | hsa-miR-221-3p | Duke C | MNDR-E-MI-30659 |
MNDR | hsa-miR-221-3p | Tubulovillous adenoma | MNDR-E-MI-30660 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAM1A | Homo sapiens | RR00040682 |
![](../images/upToTop.png)